Table 1.
Lesion characteristics
| Lesions characteristics | tCho (R1, mmol/kg)# |
tCho (R2, mmol/kg)# |
p value | ||
|---|---|---|---|---|---|
| Malignant lesion histological subtypes | n = 74 | 3.22 (2.07, 7.17; 0.23–15.89) | 3.29 (1.83, 7.28; 0.22–16.00) | ||
| Invasive ductal carcinoma NST | 57 | 2.82 (2.01, 7.32; 0.23–15.89) | 2.95 (1.78, 7.32; 0.22–16.00) |
0.346 (R1), 0.301 (R2) |
|
| Invasive lobular carcinoma | 12 | 4.36 (2.66, 7.51; 1.04–11.19) | 4.20 (2.94, 8.45; 1.41–11.01) | ||
| Ductal carcinoma in situ | 2 | 3.57 (3.03, 4.12; 3.03–4.12) | 3.29 (3.26, 3.32; 3.26–3.32) | ||
| Other§ | 3 | 1.79 (0.99, 2.87; 0.73–3.23) | 1.96 (1.03, 2.68; 0.72–2.93) | ||
| Malignant lesion grading | n = 74 | ||||
| G1 | 5 | 1.65 (1.07, 4.79; 0.62–7.79) | 1.74 (1.01, 5.50; 0.49–9.05) |
0.200 (R1), 0.264 (R2) |
|
| G2 | 26 | 3.57 (2.65, 7.41; 0.23–15.89) | 3.70 (2.67, 7.62; 0.22–16.00) | ||
| G3 | 43 | 3.11 (1.82, 6.30; 0.54–13.22) | 3.10 (1.75, 6.33; 0.83–13.17) | ||
| Malignant lesion receptor status | n = 73* | ||||
| HR+, her2neu− | 38 | 4.42 (2.62, 7.94; 0.23–15.89) | 4.25 (2.66, 4.27; 0.22–16.0) |
0.051 (R1), 0.056 (R2)x |
|
| HR+, her2neu+ | 15 | 3.20 (2.67, 4.09; 1.70–7.32) | 2.95 (2.66, 4.27; 1.41–8.73) | ||
| HR−, her2neu+ | 6 | 2.41 (1.58, 2.48; 1.33–4.00) | 2.37 (1.51, 2.42; 1.29–3.71) | ||
| HR−, her2neu− | 14 | 1.95 (1.69, 6.47; 0.84–11.19) | 1.81 (1.70, 6.74; 0.83–11.01) | ||
| Lymph node status | n = 63* | ||||
| LN+ | 17 | 7.17 (3.78, 8.43; 2.48–13.22) | 8.19 (3.81, 8.81; 2.42–13.17) | 0.002 (R1), < 0.001 (R2) | |
| LN− | 46 | 2.79 (1.75, 2.66; 0.23–15.89) | 2.86 (1.71, 4.92; 0.22–16.00) | ||
| Benign lesions | n = 29 | 0.93 (0.27, 2.55; 0.00–6.00) | 1.13 (0.27, 2.57; 0.00–6.06) | ||
| Epithelial proliferations | 15 | 1.07 (0.13, 2.94; 0.00–6.00) | 1.10 (0.11, 2.89; 0.00–6.06) |
0.919 (R1), 0.872 (R2) |
|
| Fibroadenoma | 8 | 1.13 (0.09, 3.37; 0.00–4.78) | 1.13 (0.09, 3.59; 0.00–5.03) | ||
| Solid B3$ | 3 | 1.93 (0.30, 2.16; 0.30–2.16) | 2.11 (0.41, 2.22; 0.41–2.22) | ||
| Inflammation | 3 | 0.73 (0.26, 0.93; 0.26–0.93) | 0.84 (0.25, 1.13; 0.25–1.13) |
* in 11 patients, no reliable reference standard for axillary lymph node status was available due to neoadjuvant treatment before surgery and in one patient no receptor status was available in a DCIS; #given as: median (interquartile range Q25, Q75, range); §one invasive papillary, mucinous, and tubular carcinoma, respectively; $two papilloma, one phyllodes; xHR+ breast cancers differed significantly from all others (p = 0.018 (R1) and p = 0.020 (R2), respectively